The European Medicines Agency (EMA) has given the “green light” for the release of the BioNTech-Pfizer vaccine within the European Union following the meeting of the competent Committee for Medicinal Products for Human Use (CHMP), protothema.gr reports.
This means the European Commission can now instantly license the vaccine for use in the EU market.
The Coreper Committee for Medicinal Products for Human Use, which includes experts from all Member States, issues a positive recommendation only when the evidence convincingly demonstrates that the benefits of the vaccine outweigh the risks of the vaccine.
The European Commission is currently in intensive negotiations to ensure a diversified range of vaccines at fair prices. Deals have been reached with AstraZeneca (400 million doses), Sanofi-GSK (300 million doses), Johnson and Johnson (doses sufficient for 400 million people), BioNTech-Pfizer (300 million doses), CureVac (405 million doses), and Moderna (160 million doses). Member States also have the option of donating vaccines to low- and middle-income countries.
RELATED TOPICS: Greece, Greek tourism news, Tourism in Greece, Greek islands, Hotels in Greece, Travel to Greece, Greek destinations, Greek travel market, Greek tourism statistics, Greek tourism report
Photo Source: Wikimedia Commons License: CC-BY-SA Copyright: European Commission
